Deoxyribonucleic acid ploidy in endometrial carcinoma: a reproducible and valid prognostic marker in a routine diagnostic setting

American Journal of Obstetrics and Gynecology

Volumn 201, Issue 6, 2009, Pages 603.e1-603.e7

  Wik, Elisabeth ^a   Trovik, Jone ^a,b   Iversen, Ole E ^a,b   Engelsen, Ingeborg B ^b   Stefansson, Ingunn M ^a,b   Vestrheim, Liv C ^b   Haugland, Hans K ^b   Akslen, Lars A ^a,b   Salvesen, Helga B ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

deoxyribonucleic acid ploidy; endometrial carcinoma; prognostic marker; survival; validation study

Indexed keywords

DNA;

AGED; ANEUPLOIDY; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; DIAGNOSTIC TEST; DNA CONTENT; DNA DETERMINATION; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; ONSET AGE; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; VALIDATION STUDY;

EID: 70749115766     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajog.2009.07.029     Document Type: Article

References (36)

1. Cancer Registry of Norway. Cancer in Norway 2005. Special edition (2005), Institute of Population-Based Cancer Research, Oslo, Norway
2. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., and Vergote I. Endometrial cancer. Lancet 366 (2005) 491-505
3. Salvesen H.B., and Akslen L.A. Molecular pathogenesis and prognostic factors in endometrial carcinoma. Apmis 110 (2002) 673-689
4. Hogberg T., Fredstorp-Lidebring M., Alm P., et al. A prospective population-based management program including primary surgery and postoperative risk assessment by means of DNA ploidy and histopathology. Adjuvant radiotherapy is not necessary for the majority of patients with FIGO stage I-II endometrial cancer. Int J Gynecol Cancer 14 (2004) 437-450
5. Lim P., Aquino-Parsons C.F., Wong F., et al. Low-risk endometrial carcinoma: assessment of a treatment policy based on tumor ploidy and identification of additional prognostic indicators. Gynecol Oncol 73 (1999) 191-195
6. Mangili G., Montoli S., De Marzi P., et al. The role of DNA ploidy in postoperative management of stage I endometrial cancer. Ann Oncol 19 (2008) 1278-1283
7. Iversen O.E. Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 155 (1986) 770-776
8. Hall P.A. DNA ploidy analysis in histopathology. DNA ploidy studies in pathology-a critical appraisal. Histopathology 44 (2004) 614-620
9. Salvesen H.B., Iversen O.E., and Akselen L.A. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 4 (1998) 2779-2785
10. The Cancer Registry of Norway. Cancer in Norway, 1996. 1st ed. (1999), Institute for Epidemiological Cancer Research, Oslo, Norway
11. Announcement. FIGO stage, 1988 revision. Gynecol Oncol 35 (1989) 125-127
12. Silverberg S.G., Kurman R.J., Nogales F., et al. Tumors of the uterine corpus. In: Tavassoli F.A., and Devilee P. (Eds). Tumours of the breast and female genital organs. World Health Organization classification of tumours: pathology and genetics. 5th ed. (2003), IACR Press, Inc, Lyons, France 217-258
13. Engelsen I.B., Stefansson I., Akslen L.A., and Salvesen H.B. Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 195 (2006) 979-986
14. Iversen O.E., Utaaker E., and Skaarland E. DNA ploidy and steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand 67 (1988) 531-537
15. Barlogie B., Raber M.N., Schumann J., et al. Flow cytometry in clinical cancer research. Cancer Res 43 (1983) 3982-3997
16. Friedlander M.L., Hedley D.W., and Taylor I.W. Clinical and biological significance of aneuploidy in human tumours. J Clin Pathol 37 (1984) 961-974
17. Fox H. Ploidy in gynaecological cancers. Histopathology 46 (2005) 121-129
18. Kodama S., Kase H., Tanaka K., and Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 53 (1996) 23-30
19. Lukes A.S., Kohler M.F., Pieper C.F., et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73 (1994) 2380-2385
20. Nordstrom B., Strang P., Bergstrom R., Nilsson S., and Tribukait B. A comparison of proliferation markers and their prognostic value for women with endometrial carcinoma. Ki-67, proliferating cell nuclear antigen, and flow cytometric S-phase fraction. Cancer 78 (1996) 1942-1951
21. Terada K., Mattson D., Goo D., and Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol 95 (2004) 483-487
22. Konski A., Domenico D., Tyrkus M., et al. Prognostic characteristics of surgical stage I endometrial adenocarcinoma. Int J Radiat Oncol Biol Phys 35 (1996) 935-940
23. Mariani A., Sebo T.J., Webb M.J., et al. Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev 27 (2003) 434-441
24. Orbo A., Rydningen M., Straume B., and Lysne S. Significance of morphometric, DNA cytometric features, and other prognostic markers on survival of endometrial cancer patients in northern Norway. Int J Gynecol Cancer 12 (2002) 49-56
25. Sorbe B., Risberg B., and Frankendal B. DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 38 (1990) 22-27
26. Braly P.S. Flow cytometry as a prognostic factor in endometrial cancer-what does it add?. Gynecol Oncol 58 (1995) 145-147
27. Lindahl B., Alm P., Fernø M., et al. Prognostic value of flow cytometrical DNA measurements in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation. Anticancer Res 7 (1987) 791-797
28. Nordstrøm B., Strang P., Lindgren A., Bergstrøm R., and Tribukait B. Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications?. Int J Gynecol Pathol 15 (1996) 191-201
29. Pradhan M., Abeler V.M., Danielsen H.E., Trope C.G., and Risberg B. Image cytometry DNA ploidy correlates with histological subtypes in endometrial carcinomas. Mod Pathol 19 (2006) 1227-1235
30. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post operative radiation therapy in endometrial carcinoma. Lancet 355 (2000) 1404-1411
31. Susini T., Amunni G., Molino C., et al. Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 109 (2007) 882-890
32. Cragun J.M., Havrilesky L.J., Calingaert B., et al. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 23 (2005) 3668-3675
33. Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K., and ASTEC Study Group. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 373 (2009) 125-136
34. Van den Bruel A., Cleemput I., Aertgeerts B., Ramaekers D., and Buntinx F. The evaluation of diagnostic tests: evidence on technical and diagnostic accuracy, impact on patient outcome and cost-effectiveness is needed. J Clin Epidemiol 60 (2007) 1116-1122
35. Herman C.J. Cytometric DNA analysis in the management of cancer. Clinical and laboratory considerations. Cancer 69 (1992) 1553-1556
36. Podratz K.C., Wilson T.O., Gaffey T.A., Cha S.S., and Katzmann J.A. Deoxyribonucleic acid analysis facilitates the pretreatment identification of high-risk endometrial cancer patients. Am J Obstet Gynecol 168 (1993) 1206-1213